NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the...
December 09 2020 - 9:00AM
Business Wire
- NantHealth’s study data shows:
- Adoption of trastuzumab biosimilars in treatment of
HER2-positive breast cancer is significant; does not appear to have
been affected by patient selection, stage of disease, or goals of
care.
- Potentially significant clinical and cost benefits of
trastuzumab biosimilars use in breast cancer treatment.
NantHealth, Inc. (NASDAQ: NH), a provider of enterprise
solutions that help businesses transform complex data into
actionable insights, today presented during a poster session at the
San Antonio Breast Cancer Symposium (SABCS) new significant
findings around the adoption of trastuzumab biosimilars in the
treatment of HER2-positive breast cancer and the potential clinical
and cost benefits of biosimilars. NantHealth’s presentation
demonstrated that the adoption of trastuzumab biosimilars does not
appear to be affected by patient selection, stage of disease, or
goals of care.
The study examined data from NantHealth’s Eviti Connect, an
evidence-based treatment decision platform that gives providers and
payers confidence to prescribe and reimburse high-quality,
high-value cancer care. The data was collected from treatment plans
submitted from June 2019 through October 31, 2020, for patients
with HER2-positive breast cancer. The study looked at the effect of
multiple factors on adoption, including physician confidence in
biosimilar efficacy and efficacy across stages, practice
reimbursement, as well as payer medical policy and redirection.
The study results indicate that adoption of trastuzumab
biosimilars has increased over time across all stages of breast
cancer. The choice of brand over biosimilar does not appear to be
based on whether a therapy is curative or palliative (biosimilar
use was higher in the curative setting) and trastuzumab biosimilar
use in practice increases when payer policy favors that use.
Consequently, the data infers an opportunity for payers to
successfully redirect providers to biosimilars that offer
high-value care at lower costs, when utilizing technology, such as
Eviti Connect. Additionally, the adoption of trastuzumab
biosimilars is estimated to impact societal savings
significantly.
“These findings are exciting as they show that the oncology
community is using biosimilars to provide high-quality cancer care
while lowering overall costs. This approach also highlights the
opportunity to apply real-world data to understand and improve the
delivery of valuable oncology care,” said William Flood, MD, Chief
Medical Officer, Eviti at NantHealth.
Presentation Details
Title: “Real-world data on the adoption of
trastuzumab biosimilars in the treatment of HER2-positive breast
cancer” Authors: William A. Flood, MD, MS; Tiffany
Avery, MD; Vlad Kozlovsky; Neil Margolis, Ph.D.; Sandeep K. Reddy,
MD Poster Number: PS9-63 Date and Time:
December 9, 2020 at 8 am CT
The San Antonio Breast Cancer Symposium, held virtually from
December 8-11, 2020, provides information on breast cancer
research, creating a forum for interaction, communication, and
education for a broad spectrum of researchers, health
professionals, and those with a special interest in breast
cancer.
About NantHealth, Inc.:
NantHealth, a member of the NantWorks ecosystem of companies,
provides enterprise solutions that help businesses transform
complex data into actionable insights. By offering efficient ways
to move, interpret, and visualize complex and highly sensitive
information, NantHealth enables customers in healthcare, life
sciences, logistics, telecommunications, and other industries to
automate, understand, and act on data while keeping it secure and
scalable. NantHealth’s product portfolio comprises the latest
technology in payer/provider collaboration platforms for real-time
coverage decision support (Eviti and NaviNet); molecular analysis
(GPS Cancer); and data solutions that provide multi-data analysis,
reporting, and professional services offerings. OpenNMS, a
NantHealth subsidiary, helps businesses monitor and manage network
health and performance. For more information, visit nanthealth.com,
follow us on Twitter, Facebook, and LinkedIn, and subscribe to our
blog.
Forward-Looking Statement
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to integrate OpenNMS into our operations;;
our ability to obtain regulatory approvals; dependence upon senior
management; the need to comply with and meet applicable laws and
regulations; unexpected adverse events; clinical adoption and
market acceptance of GPS Cancer; and anticipated cost savings. We
undertake no obligation to update any forward-looking statement in
light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201209005288/en/
MEDIA CONTACT Jen Hodson NANT Jen@nant.com
562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024